Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
09/16/2021 09/17/2021 09/22/2021 09/23/2021 09/24/2021 Date
57.51 58.7 57.03 57.01 57.32 Last
35264940 33435360 26105280 22482920 22708400 Volume
-3.12% +2.07% -2.84% -0.04% +0.54% Change
Estimated financial data (e)
Sales 2021 37 550 M 5 807 M 5 807 M
Net income 2021 4 674 M 723 M 723 M
Net Debt 2021 17 898 M 2 768 M 2 768 M
P/E ratio 2021 31,0x
Yield 2021 0,89%
Sales 2022 43 540 M 6 734 M 6 734 M
Net income 2022 6 259 M 968 M 968 M
Net Debt 2022 16 166 M 2 500 M 2 500 M
P/E ratio 2022 24,2x
Yield 2022 1,25%
Capitalization 115 B 17 827 M 17 827 M
EV / Sales 2021 3,55x
EV / Sales 2022 3,02x
Nbr of Employees 34 375
Free-Float 57,5%
More Financials
Company
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company's products are mainly applied in the treatment of metabolism and digestive tract system, cardiovascular system, central nervous system, blood system, anti-tumor and anti-infection diseases. The Company is also engaged in medical... 
Sector
Pharmaceuticals
Calendar
11/01Earnings Release
More about the company
Ratings of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
09/22SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Raises Nearly $186 Million from Sale of Renmi..
MT
09/21SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Wins US FDA Nod to Start Clinical Trial of Ex..
MT
09/21SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement - on completion of the issuance of ..
PU
09/10SHANGHAI FOSUN PHARMACEUTICAL : Proposed adoption of rsu scheme by a subsidiary (h ..
PU
09/02SHANGHAI FOSUN PHARMACEUTICAL : Monthly return of equity issuer on movements in securities..
PU
09/01Helped by TSMC and Foxconn, BioNTech vaccines finally reach Taiwan
RE
09/01SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Secures Another $100 Million For COVID-19 Vac..
MT
08/25REFILE-Taiwan says BioNTech shots available earlier than expected
RE
08/25REFILE-Taiwan to get BioNTech shots early as China delays approval-source
RE
08/24SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Announces 2021 Interim Results Innovative Pro..
PU
08/24SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharmaceutical H1 Profit Rises 45% Amid Higher Reven..
MT
08/24SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Offloads Entire 25% Stake in Tianjin Pharmace..
MT
08/24Tianjin Kingyork Group Co., Ltd. signed the Equity Transfer agreement to acquire an add..
CI
08/23SHANGHAI FOSUN PHARMACEUTICAL : Interim results announcement for the six months ended 30 j..
PU
08/23SHANGHAI FOSUN PHARMACEUTICAL : REVISION OF ANNUAL CAP OF CONTINUING CONNECTED TRANSACTION..
PU
More news
News in other languages on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
09/22Fosun Pharma lève près de 186 millions de dollars grâce à la vente d'obligations en ren..
09/21Fosun Pharma obtient le feu vert de la FDA pour lancer l'essai clinique d'un traitement..
09/01Fosun Pharma obtient 100 millions de dollars supplémentaires pour la production du vacc..
07/16BIONTECH : à la rescousse de la Chine
07/16PLANÈTE BOURSEá : La revue de presse du vendredi 16 juillet 2021
More news
Analyst Recommendations on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
More recommendations
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | 600196 | CNE000000X38 | MarketScreener
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 57,32 CNY
Average target price 68,40 CNY
Spread / Average Target 19,3%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman